FDA Brief

Warning letters Drugs

FDA warning letter to

Skyless, LLC

High riskIssued Jan 23, 2023Posted Feb 28, 2023Division of Pharmaceutical Quality Operations II

FDA cited Skyless, LLC for CGMP failures and for selling three X-PASMO topical analgesic ointments as unapproved and misbranded drugs.

What happened

FDA inspected Skyless's drug manufacturing facility in Ponce, Puerto Rico, from May 2 to May 16, 2022. FDA found CGMP violations including no analytical or microbiological release testing for batches, no identity testing of incoming raw materials and no supplier qualification, and an inadequate quality unit. FDA also reviewed the firm's website and labels and found three X-PASMO topical analgesic ointments marketed as unapproved new drugs and misbranded.

What FDA found

  1. Skyless did not perform laboratory release testing for each batch, including identity and strength of active ingredients, before distributing its OTC topical drug products.

    21 CFR 211.165(a)
  2. Skyless did not test incoming raw materials and active ingredients for identity and did not qualify suppliers or verify their certificates of analysis.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  3. The quality unit did not ensure adequate written procedures, ongoing process monitoring, cleaning validation, or equipment maintenance.

    21 CFR 211.22; 21 CFR 211.100(a); 21 CFR 211.67(b)
  4. The three X-PASMO ointments are unapproved new drugs because they are not generally recognized as safe and effective and have no FDA-approved application.

    FD&C Act section 505(a), 21 U.S.C. 355(a)
  5. The three X-PASMO ointments are misbranded because they are nonprescription drugs that do not meet section 505G marketing requirements and lack approved applications.

    FD&C Act section 502(ee), 21 U.S.C. 352(ee)
  6. The Manteca de Ubre product label has Spanish on the principal display panel but the Drug Facts panel only in English, violating foreign-language labeling requirements.

    FD&C Act section 502(c), 21 U.S.C. 352(c); 21 CFR 201.15(c)(2)-(3)

What FDA wants

FDA asks Skyless to provide independent assessments, remediation plans, test methods, supplier qualification and cleaning/process validation procedures, and CAPA, and to correct the unapproved drug and misbranding issues. The excerpt does not include a response deadline.

Who should pay attention

  • contract manufacturers and brands selling OTC topical analgesics
  • companies relying on supplier certificates of analysis without identity testing
  • firms marketing OTC drugs under monograph claims

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk